Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Agammaglobulinemia 1

Interventions

Cyclophosphamide 172Rituximab 161Specimen Handling 115Biopsy 92Magnetic Resonance Spectroscopy 90Vincristine 88Doxorubicin 82Prednisone 80fludarabine 71venetoclax 70obinutuzumab 63Lenalidomide 56ibrutinib 55Dexamethasone 55Cytarabine 49Methotrexate 47acalabrutinib 43Etoposide 43CT-P10 41blinatumomab 38fludarabine phosphate 35Bendamustine Hydrochloride 35Gemcitabine 33prednylidene 32zanubrutinib 31deltacortene 31pembrolizumab 30Calcium Dobesilate 30glofitamab 29Nivolumab 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Panzyga × Lymphoid × 90 days × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡